保留射血分数的心力衰竭病理生理机制和治疗的研究进展

doi:10.13481/j.1671-587x.20190244

[1] ROSCANI M G, MATSUBARA L S, MATSUBARA B B. Heart failure with normal ejection fraction[J]. Arq Bras Cardiol,2010, 94(5):652-660, 694-702.
[2] ASRAR UI, HAQ M, MUTHA V, et al.Heart failure with preserved ejection fraction-unwinding the diagnosis mystique[J].Am J Cardiovasc Dis, 2014, 4(3):100-113.
[3] DONG S, MA W, HAO B, et al.MicroRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2[J].Int J Clin Exp Pathol, 2014, 7(2):565-574.
[4] YTURRALDE R F, GAASCH W H.Diagnostic criteria for diastolic heart failure[J].Prog Cardiovasc Dis, 2005, 47(5):314-319.
[5] PONIKOWSKI P, VOORS A A, ANKER S D, et al.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC).Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail, 2016, 18(8):891-975.
[6] RØEÅ T, SJAASTAD I, LOUCH W E.Heart failure with preserved ejection fraction[J].Tidsskr Nor Laegeforen, 2017, 137(18).DOI:10.4045/tidsskr.16.1068.
[7] HEINZEL F R, HOHENDANNER F, JIN G, et al.Myocardial hypertrophy and its role in heart failure with preserved ejection fraction[J].J Appl Physiol, 2015, 119(10):1233-1242.
[8] WESTERMANN D, LINDNER D, KASNER M, et al.Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction[J].Circ Heart Fail, 2011, 4(1):44-52.
[9] TSCHÖPE C, VAN LINTHOUT S, KHERAD B.Heart failure with preserved ejection fraction and future pharmacological strategies:A glance in the crystal ball[J].Curr Cardiol Rep, 2017, 19(8):70.
[10] ROSENDORFF C.The chicken and the egg:Sympathetic nervous system activity and left ventricular diastolic dysfunction[J].Hypertension, 2009, 53(2):108-109.
[11] AIKAWA T, NAYA M, OBARA M, et al.Impaired myocardial sympathetic innervation is associated with diastolic dysfunction in heart failure with preserved ejection fraction:¹¹C-hydroxyephedrine PET study[J].J Nucl Med, 2017, 58(5):784-790.
[12] MOHAMMED S F, HUSSAIN S, MIRZOYEV S A, et al.Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction[J].Circulation, 2015, 131(6):550-559.
[13] GONZALEZ-LO PEZ E, GALLEGO-DELGADO M, GUZZO-MERELLO G, et al.Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction[J].Eur Heart J, 2015, 36(38):2585-2594.
[14] JOVIN I S, EBISU K, LIU Y H, et al.Left ventricular ejection fraction and left ventricular end-diastolic volume in patients with diastolic dysfunction[J].Congest Heart Fail, 2013, 19(3):130-134.
[15] ZǍGREANU V M, POP D, ZDRENQHEA M, et al.Plasmatic levels of N-terminal pro-BNP in elderly patients with atrial fibrillation and heart failure with preserved ejection fraction[J].Iran J Public Health, 2017, 46(4):568-570.
[16] HSIAO S H,LIN K L,CHIOU K R.Comparison of left atrial volume parameters in detecting left ventricular diastolic dysfunction versus tissue Doppler recordings[J].Am J Cardiol, 2012, 109(5):748-755.
[17] TANNENBAUM S, SAYER G T.Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction[J].Curr Opin Cardiol, 2015, 30(3):250-258.
[18] PANDEY A, DARDEN D, BERRY J D.Low fitness in midlife:a novel therapeutic target for heart failure with preserved ejection fraction prevention[J].Prog Cardiovasc Dis, 2015, 58(1):87-93.
[19] LÓPEZ B, RAVASSA S, GONZÁLEZ A, et al.Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure[J].J Am Coll Cardiol, 2016, 67(3):251-260.
[20] MOHAMMED S F, BORLAUG B A, ROQER V L, et al.Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction:A community-based study[J].Circ Heart Fail, 2012, 5(6):710-719.
[21] LINDMAN BR, DÁVILA-ROMÁN V G, MANN D L, et al.Cardiovascular phenotype in HFpEF patients with or without diabetes:a RELAX trial ancillary study[J].J Am Coll Cardiol, 2014, 64(6):541-549.
[22] ZAKERI R, BORLAUG B A, MCNULTY S E, et al.Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction:a RELAX trial ancillary study[J].Circ Heart Fail, 2014, 7(6):123-130.
[23] GORI M, SENNI M, GUPTA D K, et al.Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction[J].Eur Heart J, 2014, 35(48):3442-3451.
[24] KONISHI M, SUGIYAMA S, SUGAMURA M, et al.Accumulation of pericardial fat correlates with left ventricular diastolic dysfunction in patients with normal ejection fraction[J].J Cardiol, 2012, 59(3):344-351.
[25] YUSUF S, PFEFFER M A, SWEDBERG K, et al.Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial[J].Lancet, 2003, 362(9386):777-781.
[26] CLELAND J G, TENDERA M, ADAMUS J, et al.The perindopril in elderly people with chronic heart failure(PEP-CHF)study[J].Eur Heart J, 2006, 27(19):2338-2345.
[27] MASSIE B M, CARSON P E, MCMURRAY J J, et al.Irbesartan in patients with heart failure and preserved ejection fraction[J].N Engl J Med, 2008, 359(23):2456-2467.
[28] EDELMANN F, WACHTER R, SCHMIDT A G, et al.Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction:the Aldo-DHF randomized controlled trial[J].JAMA, 2013, 309(8):781-791.
[29] PITT B, PFEFFER M A, ASSMANN S F, et al.Spironolactone for heart failure with preserved ejection fraction[J].N Engl J Med, 2014, 370(15):1383-1392.
[30] CONRAADS V M, METRA M, KAMP O, et al.Effects of the long-term administration of nebivolol on the clinical symptoms,exercise capacity,and left ventricular function of patients with diastolic dysfunction:results of the ELANDD study[J].Eur J Heart Fail, 2012, 14(2):219-225.
[31] YAMAMOTO K, ORIGASA H, HORI M, et al.Effects of carvedilol on heart failure with preserved ejection fraction:the Japanese Diastolic Heart Failure Study(J-DHF)[J].Eur J Heart Fail, 2013, 15(1):110-118.
[32] AHMED A, RICH M W, FLEG J L, et al.Effects of digoxin on morbidity and mortality in diastolic heart failure:the ancillary digitalis investigation group trial[J].Circulation, 2006, 114(5):397-403.
[33] REDFIELD M M, BORLAUG B A, LEWIS G D, et al.Phosphdieste RasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure(RELAX) trial:Rationale and design[J].Circ Heart Fail,2012, 5(5):653-659.
[34] KOSMALA W, HOLLAND D J, ROJEK A, et al.Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction:A randomized trial[J].J Am Coll Cardiol, 2013,62(15):1330-1338.
[35] GORI M, SENNI M.Sacubitril/valsartan(LCZ696)for the treatment of heart failure[J].Expert Rev Cardiovasc Ther, 2016, 14(2):145-153.
[36] RASTOGI S, SHAROV V G, MISHRA S, et al.Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure[J].Am J Physiol Heart Circ Physiol, 2008, 295(5):H2149-H2155.
[37] MAIER LS, LAYUG B, KARWATOWSKA-PROKOPCZUK E, et al.RAnolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction;the RALI-DHF proof-of-concept study[J].JACC Heart Fail, 2013, 1(2):115-122.
[38] KITZMAN D W, BRUBAKER P H, MORGAN T M, et al.Exercise training in older patients with heart failure and preserved ejection fraction:A randomized,controlled,single-blind trial[J].Circ Heart Fail, 2010, 3(6):659-667.

Research progress in pathophysiological mechanism and treatment of heart failure with preserved ejection fraction

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	HE Qi, SHI Hua, DAN Yang, SHAO Suju. Effects of Jiawei Danshen Yin on cardiac function and serum inflammatory factors IL-6 and TNF-α in rats with chronic heart failure [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 63-68.
[2]	WEI Qun, YANG Ping. Effects of telmisartan on expressions of activin A and its receptors in non-infarction area of left ventricle in heart failure rats after myocardial infarction [J]. Journal of Jilin University Medicine Edition, 2017, 43(03): 468-473.
[3]	ZHAO Yanan, DENG Honghua, YANG Ping. Clinical significance of heart rate turbulence in prognosis assessment of patients with chronic heart failure [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 374-378.
[4]	WANG Xiao-qin,DU Yan-wei,WEN Nai-yan,CHU Hong-shuo,LI Na,ZHU Bi-tao,LU Yu-ming,ZHAO Li-jing. Protective effect of Panaxadiol Saponins on acute alcohol myocardial injury in rabbits and mechanism [J]. Journal of Jilin University Medicine Edition, 2014, 40(03): 471-475.
[5]	LI Bing,HE Min,TONG Ya-liang,FENG Zhao-hui,YANG Ping. Evaluation on efficacy and safety of tolvaptan in treatment of hyponatremia in patients with chronic heart failure [J]. Journal of Jilin University Medicine Edition, 2013, 39(5): 995-998.
[6]	WU Guo-dong，WANG　Su-xia,JI Zhi-yong， ZHANG Shu-yan. Relationship between B-type natriuretic peptide level and liver  function of rats with acute heart failure [J]. Journal of Jilin University Medicine Edition, 2013, 39(3): 517-520.
[7]	HAN Xi\|QI Ya-ling\|HU Qing-yun\|TIAN Guo-zhong\|WANG Pei-jun\|OU Ye-tao\|ZHANG . Effect of growth hormone releasing peptide \|on IL-1&beta\|level in myocardium tissue \|of chronic heart failure rats  [J]. J4, 2012, 38(3): 490-494.
[8]	DING Da-zhi,DING Jiang-shan,JIN Zhen-yi,QIN Xiao-zhi,GUAN Li-ke,CUI Xun. Evaluation of curative effect of meglumine cyclic adenylate combined with recombinant human brain natriuretic peptide in treatment of coronary artery disease patients with heart failure [J]. J4, 2011, 37(4): 723-726.
[9]	DING Mei, YANG Ping, HE Min, FENG Chao-Hui. Evaluation of curative effects of Qiliqiangxin capsule in treatment of patients with chronic congestive heart failure [J]. J4, 2009, 35(6): 1147-1150.
[10]	ZHENG Yan, MENG Lin, DONG Jun-Shu, WUN Jin-Yi. Effect of carvedilol on heart function and glucolipometabolic in elder patients with diastolic heart failure [J]. J4, 2009, 35(6): 1111-1114.
[11]	. Evaluation of Echo-Tracking technique for vascular endothelial function in patients with chronic heart failure [J]. J4, 2007, 33(3): 598-599.
[12]	CUI Xin-ming ,LI Yan-ru, LU Wen-wei ,CAO Xia ,WU Xuan-chen,CUI Li，YANG Shi-jie. Effects of YiXinTong pellet on ultrastructure of myocardium in canine model with acute myocardial infarction [J]. J4, 2006, 32(6): 1023-1025.
[13]	. Effects of valsartan and perindopril on left ventricular remodeling in heart failure [J]. J4, 2005, 31(6): 949-951.
[14]	. Clinical effects　of Carvedilol on dilated cardiomyopathycongestive heart failure [J]. J4, 2005, 31(4): 618-620.
[15]	FENG Jingyuan, LI Shucheng, WANG Hong, HUANG Xiansheng, ZHANG Aiwen, WANG Wenfeng. Improvement effect of curcumin on Renin-angiotensin-aldosterone system and heart funotion in rats with chronic heart failure [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 325-330.